APA (7th ed.) Citation

Noronha, K. J., Lucas, K. N., Paradkar, S., Edmonds, J., Friedman, S., Murray, M. A., . . . Bindra, R. S. (2024). NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. Molecular cancer research, 22(10), 973-988. https://doi.org/10.1158/1541-7786.MCR-23-1003

Chicago Style (17th ed.) Citation

Noronha, Katelyn J., et al. "NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion." Molecular Cancer Research 22, no. 10 (2024): 973-988. https://doi.org/10.1158/1541-7786.MCR-23-1003.

MLA (9th ed.) Citation

Noronha, Katelyn J., et al. "NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion." Molecular Cancer Research, vol. 22, no. 10, 2024, pp. 973-988, https://doi.org/10.1158/1541-7786.MCR-23-1003.